If you are an Indian adult in your late thirties or forties and the weight has crept up despite a diet history you would rather not recount, the numbers are not on your side, but they are on your radar for a reason. Across this decade, diabetes prevalence roughly doubles: national survey data put diagnosed diabetes at 9.19% among 35 to 49-year-olds, against about 5% in the 20 to 35 decade. This is the window where fatty liver is first detected, central fat accumulates, and a metabolic problem invisible at 30 becomes measurable. The good news buried in the same data: much of it is catchable, and some reversible.

• Diagnosed diabetes reaches 9.19% at ages 35 to 49 and prediabetes 6.63% (NFHS-4, n=718,597), roughly double the late-twenties rate.
• Among Indians aged 45 and over, half already have dysglycaemia, diabetes or prediabetes combined (ICMR-INDIAB analysis).
• Fatty liver in Indian cohorts is commonly first detected between 30 and 50, jumping from 6.7% under 35 to 39.4% at 35 and over in one community study.
• South Asians are diagnosed with type 2 diabetes about 9.8 years earlier than white Europeans in UK primary care. Three specific limits govern how far that finding can be applied to Indian residents.
• Prediabetes is not one-way: in a 10-year urban cohort, about 60% reverted to normal glucose early on.

The clearest picture comes from the National Family Health Survey (NFHS-4), a nationally representative survey of 718,597 Indian adults aged 18 to 54 with blood glucose measured at home, using WHO diagnostic cut-offs (a fasting glucose of 126 mg/dL or above for diabetes and 100 to 125 mg/dL for prediabetes).

The curve has a distinct kink in mid-life. Prevalence rises modestly through the twenties, then steepens sharply.

18 to 25 years: Diabetes affected 3.75% of adults in this age group, while 4.56% had prediabetes.

26 to 34 years: Diabetes prevalence increased to 4.98%, while prediabetes also reached 4.98%.

35 to 49 years: Diabetes prevalence rose to 9.19%, almost twice the level seen among adults aged 26 to 34, while prediabetes reached 6.63%.

Men aged 50 to 54 years: Diabetes prevalence reached 15.22%, with 7.18% having prediabetes.

The proportion with diagnosed high blood sugar roughly doubles between the late twenties and the late forties. Because NFHS-4 uses broad age bands, the exact turning point cannot be pinned down. The larger ICMR-INDIAB survey (113,043 adults) shows the same rise with age, suggesting a genuine mid-life steepening rather than a data artefact.

The picture past 45 is starker. A secondary analysis of ICMR-INDIAB data found dysglycaemia, diabetes plus prediabetes together, at 50.3% of adults aged 45 and older.

One of the most robust findings in this space does not come from India at all, and it matters how it is read. In the largest UK primary-care dataset, South Asians were diagnosed 9.8 years earlier with type 2 diabetes than white Europeans treated in the same health system (Mathur et al., 2020, CPRD, 179,886 incident cases, 2004 to 2017). Mean age at diagnosis was 52.6 years for South Asians versus 63.2 for white patients. The finding replicates independently in a Dutch cohort, where the raw gap was 10.9 years.

Three limits govern how far this can be pushed. It is a finding about age at clinical diagnosis of diabetes, not about when insulin resistance first begins, which has never been directly measured in either group. It is a migrant-cohort comparison, UK and Dutch South Asians against co-resident white Europeans. No study compares India-resident adults with Western-resident ones. And it describes a diagnosis-age gap, not a claim about disease biology. India-resident data, such as the ICMR-INDIAB rise in diabetes through the 25 to 34 and 35 to 44 age bands, is consistent with the pattern and is why it reads across, but it is corroboration, not the source.

The lower-weight half of the finding is where it lands hardest for readers here. At the point of diagnosis, South Asians in the UK cohort had a mean BMI of 29.7 kg/m² versus 32.3 for white patients. Type 2 diabetes was arriving at a weight that a Western BMI chart would still call merely "overweight." This is the clinical logic behind India's lower thresholds: overweight from a BMI of 23 kg/m² and obesity from 25, against Western cut-offs of 25 and 30.

Fatty liver disease, sometimes called MASLD (metabolic dysfunction-associated steatotic liver disease) or non-alcoholic fatty liver disease, is fat building up in the liver without alcohol as the cause. It tracks closely with obesity, diabetes and abnormal blood lipids, and in Indian cohorts it tends to surface in exactly this age window.

An Indian meta-analysis of 50 studies (23,581 adults, ultrasound-diagnosed) put adult pooled prevalence at 38.6%. A Goa community study of adults over 30 found NAFLD in 6.7% of those under 35 but 39.4% past age 35, with the authors noting the common age of presentation in India runs between 30 and 50. Fatty liver is already common in Indian adults by 30 to 50, especially once diabetes or central obesity is present.

The word "prediabetes" reads like a countdown, but Indian cohort data is more encouraging. Progression and regression both happen, and the balance depends heavily on the setting.

A 10-year urban cohort of 1,670 adults over 30 gives an everyday picture: annual progression of about 4.2%, a 10-year probability of moving from prediabetes to diabetes around 30%, and reversion to normal glucose peaking near 60% in the first two to three years. A national analysis found regression to normal roughly three times more likely than progression from normal to prediabetes.

Two predictors recur across cohorts: each 0.5% higher HbA1c (a three-month glucose average) raised progression odds about 1.8-fold, and each 5 cm larger waist about 1.5-fold. Both are modifiable, which is why the same diagnosis lands very differently depending on what happens next.

In Indian bodies, BMI alone is not enough, because the thin-fat phenotype means normal weight can still hide high internal fat. The Endocrine Society of India obesity guidelines (2022) build a workup around body measurement plus a small panel of blood tests.

Waist circumference: Measures central or abdominal fat. In Indian adults, a waist circumference of 90 cm or more in men or 80 cm or more in women is flagged as raised.

Waist-to-height ratio: Assesses central fat relative to body frame. A ratio above 0.5 is considered raised.

Fasting glucose and HbA1c: These assess diabetes and prediabetes. A fasting glucose of 126 mg/dL or above and an HbA1c of 6.5% or above are flagged at the diabetes threshold.

Fasting lipid profile: Checks cholesterol and triglycerides. The results are interpreted according to the individual's clinical context rather than against a single threshold.

Liver tests and ultrasound: ALT and AST help assess liver health, while ultrasound can identify fatty liver (steatosis). Persistent enzyme elevation or steatosis on imaging should be clinically assessed.

Blood pressure, TSH and uric acid: These provide information about broader metabolic and thyroid risk. Their significance is assessed based on the individual's overall clinical picture.

The practical sequence to follow if you have any metabolic risk factor:

1. Measure waist circumference at the same point every time (just above the hip bone) and compare against the Indian cut-offs.
2. Test fasting glucose and HbA1c at least once by around 40, then repeat every one to three years if normal, more often if borderline.
3. Review a fasting lipid profile for triglycerides and the triglyceride-to-HDL ratio, which describes insulin resistance better than total cholesterol.
4. Add liver tests (ALT, AST) and an ultrasound if central obesity or a glucose abnormality is already present.
5. Ask your clinician to interpret the combination, since no single number is a verdict on its own.

Most metabolic risk at this age is managed in primary care. A few situations, though, point toward a specialist.

• Confirmed type 2 diabetes in a lean or thin-fat person, or prediabetes with a very high short-term progression risk (HbA1c near 6.4% with central obesity and strong family history), often warrants an endocrinologist or diabetologist.
• Fatty liver on ultrasound with persistently raised liver enzymes despite lifestyle change, or any signal of fibrosis, warrants a hepatologist or gastroenterologist, since South Asian liver disease can progress faster.
• Where BMI reaches 27 kg/m² with at least one obesity-related condition, Indian guidelines point toward specialist obesity care rather than a one-off health check.

If your own numbers are starting to drift, understanding them is the first move, not a verdict on you. The same risks compound with age, which is why understanding obesity after 50 matters as much as acting now.

A metabolic picture, not just a scale reading. A structured body-composition and metabolic assessment with Voy's clinical team turns scattered readings into a plan. Where obesity is involved, the assessment treats it as the medical condition it is rather than a matter of willpower. Any decision about care sits with a registered clinician after a proper consultation.

This article is for general information and education only and is not medical advice, diagnosis, or treatment. GLP-1 and other medications referenced are prescription-only and are appropriate only for certain people under the supervision of a qualified clinician. Do not start, stop, or change any medication based on this article. Please consult a registered medical practitioner about your individual circumstances. Information reflects what was available at the time of review and may change.